Compare RCMT & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | MXCT |
|---|---|---|
| Founded | 1971 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.7M | 160.0M |
| IPO Year | N/A | 2021 |
| Metric | RCMT | MXCT |
|---|---|---|
| Price | $20.00 | $1.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $7.50 |
| AVG Volume (30 Days) | 33.4K | ★ 623.7K |
| Earning Date | 03-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $309,840,000.00 | $34,419,000.00 |
| Revenue This Year | $16.29 | N/A |
| Revenue Next Year | $6.92 | $11.16 |
| P/E Ratio | $11.76 | ★ N/A |
| Revenue Growth | ★ 13.70 | N/A |
| 52 Week Low | $13.18 | $1.11 |
| 52 Week High | $28.27 | $4.90 |
| Indicator | RCMT | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 22.94 |
| Support Level | $19.65 | $1.19 |
| Resistance Level | $21.06 | $1.28 |
| Average True Range (ATR) | 0.69 | 0.08 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 44.63 | 12.50 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.